HOME
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers GST Information

KeyMilestones4

2010

Emerges the 5th largest Generic Player in the US

2009

Acquires the US rights for Antara®

Acquires majority stake in MultiCare Pharmaceuticals Philippines Inc.

2008

Sets up a Biotech facility at Pune

Expands its product basket in Japan-Kyowa and receives approvals for ten products from the Ministry of Health & Labour Welfare, Japan

Acquires Hormosan Pharma GmbH in Germany

Acquires a stake in Generic Health Pty Ltd., Australia

Acquires a majority stake in Pharma Dynamics, South Africa

2007

Acquires Kyowa Pharmaceutical Industry Company Ltd., a leading Generics Company in Japan

Acquires Vadodara based Rubamin Laboratories Ltd. (rechristened to Novodigm Ltd.)

Starts commercial production at the new finished dosage facility at Jammu

2006

Receives the MHRA (UK) and WHO approval for Goa

Maiden Bonus shares issued in the ratio of 1:1

Maiden issue of Foreign Currency Convertible Bonds (FCCB) aggregating USD 100 million, listed on the Singapore Stock Exchange

2005

Receives US FDA approval for new Lovastatin plant at Tarapur

Receives the US FDA approval for Goa

Launches its Generics Business in the US with four products

Implements maiden Employees Stock Option Plan

2004

Commences its US Brands Business with the launch of Suprax®

2003

Receives WHO approval for state-of-the-art formulation plant, Aurangabad

Successfully implements SAP ERP across the Company to unify all business functions and processes

Introduced collaborative messaging and workflow solution on the intranet

Receives US FDA approval for the Oral Cephalosporin plant at Mandideep

Lupin Pharmaceuticals Inc. USA, was formed for trading, marketing and developmental activities in the US

2002

Exports to the Advanced Markets cross ` 1000 million; rising trend of exports as a % of total revenue which went up 33% year-over-year

Patent filings cross 100

First five ANDAs filed

Filed five ANDAs

New Anti-TB facility commissioned at Aurangabad*

Rablet rated by ORG-Marg as the second best launch of FY 2002-03

2001

State-of-the-art R&D Centre, Lupin Research Park at Pune is commissioned

Commences supply of Cephalosporin bulk actives to its alliance partners in the US

Lupin Laboratories Ltd. is amalgamated with Lupin Chemicals Ltd., and retitled to Lupin Ltd.

Becomes the only Asian pharmaceutical company to receive US FDA approvals for its sterile Cephalosporin facility

A state-of-the-art US FDA approved Oral Cephalosporin bulk active plant is commissioned at Mandideep